Minakem Generic APIs Minakem Generic APIs

X
[{"orgOrder":0,"company":"Delic Corp","sponsor":"Ketamine Wellness Centers","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ketamine Wellness Centers Partners with Veterans Affairs (VA) Community Care Network to Provide Free Ketamine Treatments to Veterans","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Delic Corp","sponsor":"Ketamine Wellness Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ketamine Wellness Centers (KWC) Launches SPRAVATO\u00ae Nasal Spray Therapy in Minneapolis, Salt Lake City and Dallas","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Delic Corp

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            SPRAVATO® (esketamine) CIII nasal spray is a nonselective, noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor – an ionotropic glutamate receptor.

            Lead Product(s): Esketamine Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: Spravato

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Ketamine Wellness Center

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Ketamine treatments have successfully repaired and improved these connections while also building new, healthy ones. PTSD damage can reappear over time if the treatment is stopped and no other support strategies are put in place.

            Lead Product(s): Ketamine Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ketamine Wellness Centers

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership October 14, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY